Skip to main content

Advertisement

Table 1 Acute, paediatric, active comparator-controlled studies in ADHD

From: Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials

Study acronym Study design Start/Stop dates Study duration (weeks) Age range (years) Numbers Inclusion criteria Exclusion criteria
HFBD [19] DB,MC,PC,R Nov 1998/Feb 9 7-12 65 ATX ADHD diagnosis, normal intelligence, minimum severity criteria PMs, <25 kg, history of BPD I/II, psychosis/OBD/seizures,on psychotropic medication, history (3 m) of drug/alcohol abuse, significant prior or current medical conditions
(Spencer;2002) 2000 62 Pbo
20 MPH
HFBK [19] DB,MC,PC,R Nov 1998/Feb 9 7-12 64 ATX ADHD diagnosis, normal intelligence, minimum severity criteria PMs,<25 kg, history of BPD I/II, psychosis/OBD/seizures, on psychotropic medication, history (3 m) of drug/alcohol abuse, significant prior or current medical conditions
(Spencer;2002) 2000 62 Pbo
18 MPH
LYAV [20] CO,DB,R June 7 on each treatment with washout in between 6-14 44 ATX ADHD diagnosis, normal intelligence, minimum severity criteria SMI, Primary sleep disorder
(Sangal;2006) 2001/October 41 MPH
2002 (SP II)
LYBI [21] DB,PC,PG,R, Aug 2002/Sep 6 6-16 222 ATX ADHD diagnosis, minimum severity criteria Seizures, BPD, psychosis, PDD, concomitant psychoactive medications, anxiety, tic disorders, lack of response/tolerability issues with previous stimulant usage
(Spencer;2002) 2003 220 MPH
74 Pbo (SPII)
LYBR [22] DB, MC, R Jan 2004/Oct 8 6-16 164 ATX ADHD, 20-60 kg, minimum severity criteria BPD, psychotic, PDD, suicide risk, other psychoactive medication usage, tics, tourettes,anxiety disorders
(Wang;2007)   2004    166 MPH   
  1. R randomised, DB double-blind, PC placebo controlled, MC-multi-centre, CO-cross-over, PG parallel group, ATX atomoxetine, MPH methylphenidate, Pbo placebo, ADHD attention deficit hyperactivitydisorder, PM poor metaboliser, BPD bipolar disorder, OBD organic brain disease, SMI serious mental illness, PDD pervasive developmental disorder.